NEA Management Company’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,909,956
| Closed | -$311M | – | 27 |
|
|
2025
Q4 | $311M | Hold |
2,909,956
| – | – | 15.88% | 2 |
|
|
2025
Q3 | $294M | Hold |
2,909,956
| – | – | 16.13% | 1 |
|
|
2025
Q2 | $184M | Hold |
2,909,956
| – | – | 13.84% | 3 |
|
|
2025
Q1 | $154M | Hold |
2,909,956
| – | – | 11.87% | 3 |
|
|
2024
Q4 | $163M | Hold |
2,909,956
| – | – | 9.19% | 4 |
|
|
2024
Q3 | $152M | Hold |
2,909,956
| – | – | 8.31% | 4 |
|
|
2024
Q2 | $119M | Hold |
2,909,956
| – | – | 8.99% | 3 |
|
|
2024
Q1 | $126M | Hold |
2,909,956
| – | – | 7.83% | 3 |
|
|
2023
Q4 | $134M | Hold |
2,909,956
| – | – | 8.92% | 3 |
|
|
2023
Q3 | $66.7M | Hold |
2,909,956
| – | – | 5.15% | 7 |
|
|
2023
Q2 | $48M | Hold |
2,909,956
| – | – | 3.66% | 10 |
|
|
2023
Q1 | $51.9M | Sell |
2,909,956
-2,000,000
| -41% | -$50.2M | 3.59% | 10 |
|
|
2022
Q4 | $143M | Sell |
4,909,956
-2,350
| -0% | -$60.4K | 8.03% | 4 |
|
|
2022
Q3 | $108M | Hold |
4,912,306
| – | – | 5.41% | 5 |
|
|
2022
Q2 | $20.4M | Hold |
4,912,306
| – | – | 1.05% | 24 |
|
|
2022
Q1 | $56.6M | Hold |
4,912,306
| – | – | 1.63% | 14 |
|
|
2021
Q4 | $49M | Hold |
4,912,306
| – | – | 0.99% | 17 |
|
|
2021
Q3 | $64.2M | Hold |
4,912,306
| – | – | 0.76% | 17 |
|
|
2021
Q2 | $96.2M | Hold |
4,912,306
| – | – | 1.25% | 12 |
|
|
2021
Q1 | $104M | Hold |
4,912,306
| – | – | 2.35% | 9 |
|
|
2020
Q4 | $143M | Hold |
4,912,306
| – | – | 3.77% | 8 |
|
|
2020
Q3 | $106M | Hold |
4,912,306
| – | – | 4.51% | 7 |
|
|
2020
Q2 | $110M | Hold |
4,912,306
| – | – | 4.4% | 10 |
|
|
2020
Q1 | $74.8M | Hold |
4,912,306
| – | – | 3.91% | 10 |
|
|
2019
Q4 | $113M | Hold |
4,912,306
| – | – | 5.33% | 7 |
|
|
2019
Q3 | $106M | Hold |
4,912,306
| – | – | 8.78% | 3 |
|
|
2019
Q2 | $108M | Hold |
4,912,306
| – | – | 7.57% | 3 |
|
|
2019
Q1 | $135M | Hold |
4,912,306
| – | – | 6.99% | 3 |
|
|
2018
Q4 | $132M | Hold |
4,912,306
| – | – | 5.24% | 3 |
|
|
2018
Q3 | $143M | Hold |
4,912,306
| – | – | 6.18% | 4 |
|
|
2018
Q2 | $154M | Hold |
4,912,306
| – | – | 7.19% | 3 |
|
|
2018
Q1 | $97.8M | Hold |
4,912,306
| – | – | 4.35% | 7 |
|
|
2017
Q4 | $143M | Buy |
+4,912,306
| New | +$130M | 5.91% | 3 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
NEA Management Company's RYTM Position: Q1 2026 in Review
NEA Management Company sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 2,909,956 shares — an estimated $311M sold.
NEA Management Company first reported a position in RYTM in Q4 2017 and held it in 33 quarters. The position peaked at $311M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- NEA Management Company reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- NEA Management Company sold 2,909,956 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $311M.
- NEA Management Company first reported a position in Rhythm Pharmaceuticals in Q4 2017 and held it in 33 quarters.
- NEA Management Company's Rhythm Pharmaceuticals position peaked at $311M in Q4 2025.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on NEA Management Company's 13F filing for Q1 2026, filed 15 May 2026.